Annexon Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $86.25 Million

Core Viewpoint - Annexon, Inc. has successfully closed a public offering of 29,423,075 shares of common stock, raising approximately $86.25 million to advance its clinical platform targeting neuroinflammation in complement-mediated diseases [1][2]. Company Overview - Annexon, Inc. is focused on developing next-generation complement inhibitors aimed at stopping neuroinflammation, with a particular emphasis on C1q, which is crucial in the inflammatory pathway [5]. - The company’s pipeline addresses three therapeutic areas: autoimmunity, neurodegeneration, and ophthalmology, targeting unmet needs for nearly 10 million people globally [5]. Offering Details - The public offering included the full exercise of underwriters' options, resulting in the issuance of an additional 4,326,922 shares at a public price of $2.60 per share, along with pre-funded warrants for 3,750,000 shares at a price of $2.599 per share [1]. - The offering was conducted under a shelf registration statement filed with the SEC, which was declared effective in April 2024 [3].